A combination of anti-PD-1 and agonist GITR Abs has been reported to induce synergistic enhancement of CD8+ T-cell function and a robust survival benefit [126], along with reduced T-cell dysfunction and increased proliferation of T cells with a precursor effector memory (EM) phenotype, which can optimize cancer immunotherapy outcomes. Here, PDCD1 is linked to cancer.